Close
FINDING CURES TOGETHER<sup>SM</sup>

Targeting DNA Methylation and Chromatin for Cancer Therapy

Thursday, March 1, 2018​   


Thursday, March 1, 2018

Welcome and Opening Keynote
5-6 p.m.

Epigenetic therapy: Bench to bedside
Jean-Pierre J. Issa, Temple University, Philadelphia, Pennsylvania


Welcome Reception
6-8:30 p.m.


Friday, March 2, 2018

Plenary Session 1: DNA Methylation and Chromatin Cross-Talk
Session Chair: Bradley E. Bernstein, Massachusetts General Hospital, Boston, Massachusetts
8-10 a.m.

Detecting and interpreting DNA methylation marks
Xiaodong Cheng, The University of Texas MD Anderson Cancer Center, Houston, Texas

Activation of oncogenes by mis-folded chromosomes
Bradley E. Bernstein

Epigenetic regulation through UHRF proteins

Scott B. Rothbart, Van Andel Research Institute, Grand Rapids, Michigan

DNA and histone methyltransferase inhibitors cooperate to increase viral mimicry in cancer cells*
Minmin Liu, Van Andel Research Institute, Grand Rapids, Michigan

Investigating the mechanisms by which ZBTB38 recognizes methylated DNA and modulates transcription*
Nicholas Hudson, University of Utah, Salt Lake City, Utah


Plenary Session 2: Environment, Inflammation, and DNA Repair
Session Chair: Susan J. Clark, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
10:30 a.m.-12:30 p.m.

Enduring epigenetic landmarks that define the cancer microenvironment
Susan J. Clark

Epigenome response to the environment, inflammation, and DNA repair: A critical player for  the early events in tumorigenesis?
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, Maryland

Enhancing anti-tumor immune response by DNA-demethylating agents
Daniel De Carvalho, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Mismatch repair proteins initiate epigenetic alterations during inflammation-driven tumorigenesis*
Heather O'Hagan, Indiana University School of Medicine, Bloomington, Indiana

DNA methylation patterns separate senescence from transformation potential and indicate cancer risk*
Hariharan Easwaran, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland


Plenary Session 3: DNMTs in Normal and Malignant Hematopoiesis
Session Chair: Margaret A. Goodell, Baylor College of Medicine, Houston, Texas
2:30-4:30 p.m.

How do DNMT3A mutations initiate AML?
Timothy J. Ley, Washington University School of Medicine, McDonnell Genome Institute, St. Louis, Missouri

Immortal HSCs and their regulation by DNA methylation
Margaret A. Goodell

Restraining the mutagenic influence of 5-methylcytosine
Ian Majewski, The Walter and Eliza Hall Institute of Medical Research, Camberwell, Australia

Genome-wide 5-hydroxymethylcytosine alterations in medulloblastoma*
Hyerim Kim, Emory University, Atlanta, Georgia

Additional short talk to be announced


Poster Session A / Reception
4:30-7 p.m.


Saturday, March 3, 2018

Plenary Session 4: TETs and 5hmC and regulation of Gene Expression
Session Chair: Lucy A. Godley, University of Chicago, Chicago, Illinois
8-10 a.m.

TET methylcytosine oxidases, immune responses and cancer  
Anjana Rao, La Jolla Institute for Allergy & Immunology, La Jolla, California

Regulation of neuroblastoma phenotype by hypoxia and 5-hydroxymethylcytosine
Lucy A. Godley

DNA modifications: From mechanisms to genome-wide profiling in cancers     ​     
Francois Fuks, Université libre de Bruxelles, Brussels, Belgium

Synthetic lethal targeting of TET2 loss in myeloid malignancies by TOP1 inhibitors*
Chang-Bin Jing, Dana-Farber Cancer Institute, Boston, Massachusetts

Additional short talk to be announced


Plenary Session 5: Targeting DNA Methylation in the Clinic
Session Chair: Maria E. Figueroa, Sylvester Comprehensive Cancer Center, University of Miami, Florida
10:30 a.m.-12:30 p.m.

DNA-hypomethylating agents in acute myeloid leukemia (AML): The role of combination therapies and their curative potential
Michael Lübbert, Comprehensive Cancer Center Freiburg, Germany​

Modulation of the immune system by epigenetic therapy in hematological cancer
Kirsten Grønbæk, University of Copenhagen, Denmark

DNA methylation in myelodysplastic syndromes: From clinical biomarkers to therapeutic targeting
Maria E. Figueroa

Discovery of selective, non-covalent small molecule inhibitors of DNMT1*
Melissa Pappalardi, GlaxoSmithKline, Collegeville, Pennsylvania

Targeting CDK9 reactivates epigenetically silenced genes in cancer*
Hanghang Zhang, Fels Institute for Cancer Research, Temple University School of Medicine, Philadelphia, Pennsylvania


Poster Session B / Lunch
12:30 p.m.-3 p.m.


Plenary Session 6: Epigenetic Modulation in the Development of Cancer
Session Chair: Benjamin P. Berman, Cedars-Sinai Medical Center, Los Angeles, California
3-5:15 p.m.         

Cancer methylation at the intersection of diverse chromatin processes
Benjamin P. Berman

Characterizing and modulating epigenetic events during melanoma initiation
Charles K. Kaufman, Washington University School of Medicine, St. Louis, Missouri

Epigenetic field induced by vicious combination of inflammatory signals
Toshikazu Ushijima, National Cancer Center Research Institute, Tokyo, Japan

p16 epimutation: Function in intestinal tumorigenesis and as a target for therapy*
Lanlan Shen, Baylor College of Medicine, Houston, Texas

Inhibition of histone methyltransferases EHMT1 and EHMT2 reduces PARP inhibitor resistance in high grade serous ovarian cancer*
Zachary Watson, University of Colorado, Aurora, Colorado

Targeted disruption of SIN3 chromatin regulator complex function inhibits metastasis and improves survival in triple negative breast cancer*
Samuel Waxman, Icahn School of Medicine at Mount Sinai, New York, New York


Sunday, March 4, 2018

Plenary Session 7: Single Cell Epigenomic Analysis
Session Chair: Wolf Reik, Babraham Institute, Cambridge, England
8-10 a.m.     

Single cell epigenome landscape of mammalian development and ageing
Wolf Reik

Single cell analysis of the dynamic epigenome
Amos Tanay, Weizmann Institute of Science , Rehovot, Israel

iPS cell technology, gene editing, and disease research
Rudolf Jaenisch, MIT Whitehead Institute for Biomedical Research, Cambridge, Massachusetts

Reprogramming of DNA and histone methylome by cancer-associated histone H3 mutations*
Chao Lu, Columbia University, New York, New York

CRISPR screening to assess genetic vulnerabilities in mutant IDH1-dependent models of different lineages*
Lindsey Rodrigues, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts


Plenary Session 8: Regulation of the Non-coding Genome
Session Chair: Paula M. Vertino, Emory University Winship Cancer Institute, Atlanta, Georgia
10:30 a.m.-12:30 p.m.      

Switching roles for DNA and histone methylation depend on evolutionary ages of human endogenous retroviruses
Peter A. Jones, Van Andel Research Institute, Grand Rapids, Michigan

Transposable elements in cancer epigenome
Ting Wang, Washington University School of Medicine, St. Louis, Missouri

Epigenetic regulation of transcriptional plasticity: Implications for cancer biology and therapy
Paula M. Vertino

The role of long noncoding RNA mediated disruption of SWI/SNF in prostate cancer*
Jesse Raab, UNC Chapel Hill, Chapel Hill, North Carolina

Epigenetic regulation of noncoding RNA in cancer and its effects on the immune microenvironment*
Katherine Chiappinelli, George Washington University, Washington, DC


Closing Remarks / Departure
12:30 p.m.


*Short talk from proffered abstract


Top of page     ​